MD Anderson and Takeda Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform
The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited today announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, ‘armored’ with IL-15, for the treatment of B-cell malignancies and other cancers.
Under the agreement, Takeda will receive access to MD Anderson’s CAR NK platform and...
Ziopharm Oncology and MD Anderson Cancer Center Announce New R&D Agreement to Expand TCR-T Program
Ziopharm Oncology, Inc., and The University of Texas MD Anderson Cancer Center today announced a new research and development agreement relating...
MD Anderson response to FDA and CDC statements on e-cigarettes
The University of Texas MD Anderson Cancer Center supports efforts by the Food and Drug Administration and the Centers for Disease Control...
Statement from MD Anderson regarding response to surveys from the Centers for Medicare and Medicaid Services
More than 140,000 people from around the world turned to our experts last year for their cancer care. Their trust in MD Anderson pushes us to set the highest standards and to continually improve and strive for excellent patient outcomes.
Late last year, MD Anderson self-reported to the Food and Drug Administration (FDA) an incident involving contaminated platelets that contributed to a patient’s death. Based on the self-reported...
Study finds macrophages’ pathway to nurture PTEN-deficient glioblastoma
A common genetic deficiency empowers glioblastoma to broadcast a molecular message to the wrong type of immune cell, summoning macrophages...
David Jaffray, Ph.D., Named Chief Technology and Digital Officer
The University of Texas MD Anderson Cancer Center today named David Jaffray, Ph.D., as its first-ever chief technology and digital officer...
MD Anderson addresses national threat of foreign influence
The impact of foreign influence across multiple sectors of the United States economy continues to be a national concern. Specific to academia...
Triple negative breast cancers can adopt reversible state that is resistant to chemotherapy
Researchers at The University of Texas MD Anderson Cancer Center have discovered that triple negative breast cancer (TNBC) cells can develop...
New report finds states must do more to ensure people at high risk can be screened for lung cancer
Lung cancer is the leading cancer killer, yet coverage of screenings for individuals at high risk for lung cancer varies across state Medicaid...
Nearly $20 million awarded by CPRIT to MD Anderson
The University of Texas MD Anderson Cancer Center today was awarded $19.6 million from the Cancer Prevention and Research Institute of Texas...
Small cell lung cancer may respond to combination of immunotherapy and DNA damage repair inhibitors
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a combination of immune checkpoint blockade and targeted...
Immunotherapy combination generates responses against castration-resistant metastatic prostate cancer
Some patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after hormonal therapy and chemotherapy...
MD Anderson study shows FGL2 protein may be an effective target for glioblastoma
Researchers at The University of Texas MD Anderson Cancer Center have discovered an immune regulator that appears to dictate glioblastoma...
Complication rates and costs of invasive lung cancer diagnostic tests may be higher than anticipated
Complication rates following invasive diagnostic procedures for lung abnormalities were twice as high in the community setting compared to...
VISTA checkpoint implicated in pancreatic cancer immunotherapy resistance
Researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment...
MD Anderson Cancer Center and Ascentage Pharma announce strategic alliance in cancer drug development
The University of Texas MD Anderson Cancer Center and Ascentage Pharma Group, Inc. today announced a five-year strategic collaboration agreement...